Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine

Nozomi Kuse; Yu Zhang; Takayuki Chikata; Hung The Nguyen; Shinichi Oka; Hiroyuki Gatanaga; Masafumi Takiguchi

doi:10.1038/s41467-022-32989-4

Nature Communications (Sep 2022)

Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine

Nozomi Kuse,
Yu Zhang,
Takayuki Chikata,
Hung The Nguyen,
Shinichi Oka,
Hiroyuki Gatanaga,
Masafumi Takiguchi

Affiliations

Nozomi Kuse: Division of International Collaboration Research and Tokyo laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University
Yu Zhang: Division of International Collaboration Research and Tokyo laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University
Takayuki Chikata: Division of International Collaboration Research and Tokyo laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University
Hung The Nguyen: Division of International Collaboration Research and Tokyo laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University
Shinichi Oka: Division of International Collaboration Research and Tokyo laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University
Hiroyuki Gatanaga: Division of International Collaboration Research and Tokyo laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University
Masafumi Takiguchi: Division of International Collaboration Research and Tokyo laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University

DOI: https://doi.org/10.1038/s41467-022-32989-4
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 11

Abstract

Read online

mRNA vaccines have been shown to prevent SARS-CoV-2 infection and reduce hospitalization and mortality rates. Here, the authors show evidence of long-term memory CD8 + T cells in individuals who received the BNT162b2 SARS-CoV-2 mRNA vaccine.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal